学术探索
学术期刊
新闻热点
数据分析
智能评审

Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid

被引：27
作者：
Saad, F [1 ]
机构：
[1] CHU Montreal, Notre Dame Hosp, Dept Urol Surg, Montreal, PQ H2L 4M1, Canada
来源：
SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 06期
关键词：
D O I：
10.1053/sonc.2002.37418
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 27
页数：9
相关论文
共 69 条
[1]   DICHLOROMETHYLENE-DIPHOSPHONATE IN PATIENTS WITH PROSTATIC-CARCINOMA METASTATIC TO THE SKELETON [J].
ADAMI, S ;
SALVAGNO, G ;
GUARRERA, G ;
BIANCHI, G ;
DORIZZI, R ;
ROSINI, S ;
MOBILIO, G ;
LOCASCIO, V .
JOURNAL OF UROLOGY, 1985, 134 (06) :1152-1154
[2]  
Adami S, 1989, Recent Results Cancer Res, V116, P67
[3]   COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY [J].
ANDERSEN, PK ;
GILL, RD .
ANNALS OF STATISTICS, 1982, 10 (04) :1100-1120
[4]   Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[5]   Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[6]   Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy [J].
Berruti, A ;
Dogliotti, L ;
Terrone, C ;
Cerutti, S ;
Isaia, G ;
Tarabuzzi, R ;
Reimondo, G ;
Mari, M ;
Ardissone, P ;
De Luca, S ;
Fasolis, G ;
Fontana, D ;
Rossetti, SR ;
Angeli, A .
JOURNAL OF UROLOGY, 2002, 167 (06) :2361-2367
[7]   Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline [J].
Berruti, A ;
Dogliotti, L ;
Bitossi, R ;
Fasolis, G ;
Gorzegno, G ;
Bellina, M ;
Torta, M ;
Porpiglia, F ;
Fontana, D ;
Angeli, A .
JOURNAL OF UROLOGY, 2000, 164 (04) :1248-1253
[8]  
Blomme EAG, 1999, PROSTATE, V39, P187
[9]   Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy? [J].
Boccardo, F .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (02) :121-132
[10]  
Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO
1234567